このエントリーをはてなブックマークに追加


ID 16408
Eprint ID
16408
フルテキストURL
95_1137.pdf 354 KB
タイトル(別表記)
Immunochemotherapy for lung cancer I. Evaluation of the immunopotentiators OK-432 and PSK
著者
野田 憲男 岡山大学医学部第2内科教室
抄録
Fifty-five patients with advanced lung cancer were divided at random into three groups. The first group of 19 patients was treated with OK-432 administered intramuscularly in addition to combination chemotherapy. The second group of 18 patients was treated with PSK in addition to combination chemotherapy. The third group of 18 patients was treated with combination chemotherapy only. There were no significant differences in age, histological type, extent of disease, Performance status or initial chemotherapy between the three treatment groups. The median survival was longer in the patients who received OK-432 (7.5 months) than that of the patients who received either PSK (7.0 months) or no immunotherapy (5.8 months), but this difference was not statistically significant. The degree of myelosuppression induced by the combination chemotherapy and the frequency of febrile episodes were less in the groups administered OK-432 and PSK. These results suggest that these immunopotentiators, especially OK-432, may be useful immunotherapeutic agents in combination with chemotherapy in advanced stages of lung cancer.
キーワード
肺癌 (lung cancer)
免疫化学療法 (immunochemotherapy)
OK-432
PSK
Randomized control study
発行日
1983-12-30
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
巻
95巻
号
11-12号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
1137
終了ページ
1143
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/95/11-12/95_11-12_1137/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/index.html
言語
日本語
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Eprints Journal Name
joma